Altre lingue Zai Lab Limited Hong Kong S.E.

Azioni

9688

KYG9887T1168

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:34 21/06/2024			Variaz. 5gg	Var. 1 gen.
13,74 ^HKD	-1,43%		-7,41%	-36,09%

20/06	Zai Lab concede ADS ai direttori indipendenti nell'ambito del piano di incentivazione	MT
14/06	I titoli azionari asiatici scambiati negli Stati Uniti con le ricevute americane di deposito tendono al ribasso nelle contrattazioni del venerdì	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Zai Lab : Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath	21/06
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	20/06
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading	14/06
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024	11/06
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D	11/06
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	04/06
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower	24/05
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	22/05
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	22/05
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	22/05
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	21/05
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug	20/05
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	20/05
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20/05
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20/05
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading	16/05
Zai Lab Announces Participation in May and June Investor Conferences	16/05
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	14/05
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China	14/05
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China	14/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Zai Lab Limited Hong Kong S.E.

Azioni

9688

KYG9887T1168

Altre lingue

Filtri